Ptc Therapeutics (PTCT) Short term Debt (2012 - 2026)

Ptc Therapeutics' Short term Debt history runs 12 years deep, the most recent figure standing at $305.0 million for Q1 2026.

• On a quarterly basis, Short term Debt rose 22.88% year-over-year to $305.0 million in Q1 2026; TTM through Mar 2026 was $305.0 million, a 22.88% increase from a year earlier, with the FY2025 full-year figure at $283.0 million, up 9.77% from the prior year.
• Short term Debt improved to $305.0 million in Q1 2026 per PTCT's latest filing, from $283.0 million in the prior quarter.
• Across five years, Short term Debt topped out at $305.0 million in Q1 2026 and bottomed at $69.9 million in Q1 2022.
• The 5-year median for Short term Debt is $227.1 million (2024), against an average of $191.5 million.
• Biggest YoY gain for Short term Debt was 238.13% in 2022; the steepest drop was 51.75% in 2022.
• Year by year, Short term Debt stood at $72.1 million in 2022, then surged by 169.32% to $194.3 million in 2023, then jumped by 32.68% to $257.8 million in 2024, then rose by 9.77% to $283.0 million in 2025, then rose by 7.79% to $305.0 million in 2026.
• Per Business Quant, the three latest PTCT Short term Debt figures stand at $305.0 million (Q1 2026), $283.0 million (Q4 2025), and $286.3 million (Q3 2025).